Travere Therapeutics, Inc. (TVTX)
52.79
-0.48
(-0.90%)
USD |
NASDAQ |
Oct 15, 16:00
53.15
+0.36
(+0.68%)
After-Hours: 04:40
Travere Therapeutics Research and Development Expense (Quarterly) : 60.28M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 60.28M |
| March 31, 2026 | 57.09M |
| December 31, 2025 | 57.87M |
| September 30, 2025 | 51.89M |
| June 30, 2025 | 49.36M |
| March 31, 2025 | 46.89M |
| December 31, 2024 | 62.07M |
| September 30, 2024 | 51.68M |
| June 30, 2024 | 54.33M |
| March 31, 2024 | 49.42M |
| December 31, 2023 | 58.75M |
| September 30, 2023 | 58.14M |
| June 30, 2023 | 66.99M |
| March 31, 2023 | 55.77M |
| December 31, 2022 | 55.64M |
| September 30, 2022 | 54.70M |
| June 30, 2022 | 58.06M |
| March 31, 2022 | 56.32M |
| December 31, 2021 | 61.88M |
| September 30, 2021 | 48.12M |
| June 30, 2021 | 51.52M |
| March 31, 2021 | 47.66M |
| December 31, 2020 | 38.09M |
| September 30, 2020 | 32.06M |
| June 30, 2020 | 30.50M |
| Date | Value |
|---|---|
| March 31, 2020 | 29.96M |
| December 31, 2019 | 36.07M |
| September 30, 2019 | 32.93M |
| June 30, 2019 | 37.64M |
| March 31, 2019 | 33.16M |
| December 31, 2018 | 31.70M |
| September 30, 2018 | 32.16M |
| June 30, 2018 | 34.17M |
| March 31, 2018 | 24.53M |
| December 31, 2017 | 19.49M |
| September 30, 2017 | 19.53M |
| June 30, 2017 | 19.40M |
| March 31, 2017 | 20.78M |
| December 31, 2016 | 20.00M |
| September 30, 2016 | 18.35M |
| June 30, 2016 | 17.59M |
| March 31, 2016 | 14.59M |
| December 31, 2015 | 15.37M |
| September 30, 2015 | 13.86M |
| June 30, 2015 | 10.37M |
| March 31, 2015 | 10.15M |
| December 31, 2014 | 14.36M |
| September 30, 2014 | 12.76M |
| June 30, 2014 | 13.44M |
| March 31, 2014 | 6.773M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| TG Therapeutics, Inc. | 95.34M |
| BioMarin Pharmaceutical, Inc. | 206.95M |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Viridian Therapeutics, Inc. | 71.46M |
| Krystal Biotech, Inc. | 13.16M |